03/18/23 9:00 PMNYSE : LPL LG Display's 65-inch OLED TV Panel Received Carbon Footprint Certification from the Carbon TrustLG Display, the world's leading innovator of display technologies, announced today that its 65- inch OLED TV panel earned the Product Carbon Footprint Certification from the Carbon Trust. LG Display's 65- inch OLED panel received this recognition from the Carbon Trust by meeting the global standard on GHG emissions throughout the entire product life cycle.RHEA-AIvery positive
03/18/23 4:00 PMNYSE : HII HII Celebrates 200 Graduates of The Newport News Shipbuilding Apprentice SchoolHII (NYSE: HII) hosted commencement exercises today, celebrating 200 graduates of the company’s Apprentice School at Newport News Shipbuilding (NNS). The ceremony was held at Liberty Live Church in Hampton. Virginia Gov. Glenn YoungkinRHEA-AIvery positive
03/18/23 3:40 PMNasdaq : INCY clinical trialIncyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoIncyte today announced new data from a Phase 2 b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation at the 2023 American Academy of Dermatology Annual Meeting, held from March...RHEA-AIpositive
03/18/23 2:40 PMNasdaq : CNTB low floatConnect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient SymptomsConnect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the...RHEA-AIneutral
03/18/23 2:10 PMOTC : UCBJY clinical trialBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksUCB, a global biopharmaceutical company, today announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa. 1 Data from the two studies showed that bimekizumab achieved...RHEA-AIvery positive
03/18/23 10:40 AMNasdaq : INCY clinical trialIncyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in VitiligoIncyte today announced new 104- week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura ® cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin. These data were presented today in two late-breaking oral presentations at the 2023...RHEA-AIneutral
03/18/23 10:03 AMNYSE : ABBV AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor TherapyAbbVie today announced new 52- week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI ®, an IL-23 inhibitor. The data were presented at a Late-Breaking Research session during the 2023 American Academy of Dermatology Annual Meeting...RHEA-AIneutral
03/18/23 10:00 AMNasdaq : REGN Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot DermatitisMore than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, March 18, 2023RHEA-AIneutral
03/18/23 7:00 AMNYSE : TAK clinical trialTakeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque PsoriasisTakeda today announced positive results from a Phase 2 b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients...RHEA-AIpositive
03/18/23 7:00 AMNasdaq : CSTL Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort StudyCastle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx ®- SCC can significantly improve metastatic risk predictions by complementing current staging...RHEA-AIvery positive
03/18/23 7:00 AMNasdaq : ARQT clinical trialhigh shortArcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual MeetingNew INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15% Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity IndexRHEA-AIneutral
03/18/23 6:15 AMOTC : VVCTY Vicat: 2022 Universal Registration Document ReleaseRegulatory News:. The Group operates in twelve countries: France, Switzerland, Italy, the United States, Turkey, Egypt, Senegal, Mali, Mauritania, Kazakhstan, India and Brazil. Founded in 1853, the Vicat Group now operates three core lines of business: Cement, Ready-Mixed Concrete and Aggregates, as well as related activities.RHEA-AIneutral
03/18/23 12:35 AMNasdaq : PHVS clinical triallow floatPositive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APACPharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2RHEA-AIneutral
03/18/23 12:01 AMNasdaq : PARA, PARAA WELCOME TO GOOD BURGER, HOME OF THE GOOD BURGER!Nickelodeon Studios and Paramount+ today announced the greenlight of GOOD BURGER 2, an all-new original movie sequel to the iconic' 90 s feature film based on the sketch from the comedy series "All That." The movie will follow Dexter Reed and original cashier, Ed, as they reunite in the present day at fast-food restaurant Good Burger with a hilarious new group of...RHEA-AIvery positive
